Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
- 1 June 2003
- journal article
- review article
- Published by Elsevier BV in Cytokine & Growth Factor Reviews
- Vol. 14 (3-4), 337-348
- https://doi.org/10.1016/s1359-6101(03)00029-7
Abstract
No abstract availableKeywords
This publication has 108 references indexed in Scilit:
- FOXO Proteins Regulate Tumor Necrosis Factor-related Apoptosis Inducing Ligand ExpressionJournal of Biological Chemistry, 2002
- Targeting death and decoy receptors of the tumour-necrosis factor superfamilyNature Reviews Cancer, 2002
- IAP proteins: blocking the road to death's doorNature Reviews Molecular Cell Biology, 2002
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002
- TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2Oncogene, 2001
- Bcl-2 over-expression and activation of protein kinase C suppress the Trail-induced apoptosis in Jurkat T cellsCell Research, 2001
- Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and DeathScience, 2001
- Genomic Organization and Transcriptional Regulation of Human Apo2/TRAIL GeneBiochemical and Biophysical Research Communications, 2000
- Safety and antitumor activity of recombinant soluble Apo2 ligandJCI Insight, 1999
- Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAILThe Journal of Experimental Medicine, 1999